Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 322-330

  Tohyama, M ^a   Watanabe, H ^b   Murakami, S ^a   Shirakata, Y ^a   Sayama, K ^a   Iijima, M ^b   Hashimoto, K ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; B7 ANTIGEN; CD137 LIGAND; CD14 ANTIGEN; CD16 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; MEXILETINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BASAL CELL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DERMIS; DERMOEPIDERMAL JUNCTION; DISEASE SEVERITY; DRUG ERUPTION; EPIDERMIS; ERYTHEMA MULTIFORME; FEMALE; HUMAN; HUMAN TISSUE; KERATINOCYTE; LYMPHOCYTE PROLIFERATION; MACULOPAPULAR RASH; MALE; MONOCYTE; PRIORITY JOURNAL; SKIN DEFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

4-1BB LIGAND; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; ANTIGENS, CD80; ANTIGENS, CD86; APOPTOSIS; CELL LINEAGE; CELL PROLIFERATION; EPIDERMAL NECROLYSIS, TOXIC; EPIDERMIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, IGG; STEVENS-JOHNSON SYNDROME;

EID: 84856233611     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10649.x     Document Type: Article

References (53)

1. Paquet P, Pierard GE,. Toxic epidermal necrolysis: revisiting the tentative link between early apoptosis and late necrosis (review). Int J Mol Med 2007; 19: 3-10.
2. Pereira FA, Mudgil AV, Rosmarin DM,. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181-200.
3. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123: 850-5.
4. Correia O, Delgado L, Barbosa IL, et al. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002; 47: 58-62.
5. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343-50.
6. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129: 466-8.
7. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225-30.
8. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-15.
9. Roujeau JC, Dubertret L, Moritz S, et al. Involvement of macrophages in the pathology of toxic epidermal necrolysis. Br J Dermatol 1985; 113: 425-30.
10. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 130: 605-8.
11. Paquet P, Paquet F, Al Saleh W, et al. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000; 22: 413-17.
12. Ziegler-Heitbrock HW,. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today 1996; 17: 424-8.
13. Myers LM, Vella AT,. Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol 2005; 26: 440-6.
14. So T, Lee SW, Croft M,. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int J Hematol 2006; 83: 1-11.
15. Lerner KG, Kao GF, Storb R, et al. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc 1974; 6: 367-71.
16. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-42.
17. Szaflarska A, Baj-Krzyworzeka M, Siedlar M, et al. Antitumor response of CD14+/CD16+ monocyte subpopulation. Exp Hematol 2004; 32: 748-55.
18. Grage-Griebenow E, Flad HD, Ernst M,. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001; 69: 11-20.
19. MacDonald KP, Munster DJ, Clark GJ, et al. Characterization of human blood dendritic cell subsets. Blood 2002; 100: 4512-20.
20. Lenschow DJ, Walunas TL, Bluestone JA,. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
21. Deeths MJ, Mescher MF,. ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1. Eur J Immunol 1999; 29: 45-53.
22. Laux I, Khoshnan A, Tindell C, et al. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin Immunol 2000; 96: 187-97.
23. Greenwald RJ, Freeman GJ, Sharpe AH,. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48.
24. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20: 143-8.
25. Bukczynski J, Wen T, Ellefsen K, et al. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101: 1291-6.
26. Alderson MR, Smith CA, Tough TW, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 1994; 24: 2219-27.
27. Vinay DS, Kwon BS,. Role of 4-1BB in immune responses. Semin Immunol 1998; 10: 481-9.
28. Arch RH, Thompson CB,. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998; 18: 558-65.
29. Takahashi C, Mittler RS, Vella AT,. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162: 5037-40.
30. Lee HW, Park SJ, Choi BK, et al. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002; 169: 4882-8.
31. Lee HW, Nam KO, Park SJ, et al. 4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur J Immunol 2003; 33: 2133-41.
32. Habib-Agahi M, Phan TT, Searle PF,. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol 2007; 19: 1383-94.
33. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47-55.
34. Mittler RS, Bailey TS, Klussman K, et al. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999; 190: 1535-40.
35. Nozawa K, Ohata J, Sakurai J, et al. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases. J Immunol 2001; 167: 4981-6.
36. Kim YJ, Broxmeyer HE,. Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells. J Hematother Stem Cell Res 2001; 10: 441-9.
37. Zhang H, Snyder KM, Suhoski MM, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007; 179: 4910-18.
38. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682-5.
39. Melero I, Bach N, Hellstrom KE, et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28: 1116-21.
40. Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst 2000; 92: 931-6.
41. Chen SH, Pham-Nguyen KB, Martinet O, et al. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther 2000; 2: 39-46.
42. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002; 109: 651-9.
43. Halstead ES, Mueller YM, Altman JD, et al. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002; 3: 536-41.
44. Waller EC, McKinney N, Hicks R, et al. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific 'effector memory' (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 2007; 110: 4360-6.
45. Lin GH, Sedgmen BJ, Moraes TJ, et al. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol 2009; 182: 934-47.
46. Zhang B, Maris CH, Foell J, et al. Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest 2007; 117: 3029-41.
47. Boyle JJ,. Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16. Clin Exp Immunol 2004; 137: 529-37.
48. Sviland L, Dickinson AM,. A human skin explant model for predicting graft-versus-host disease following bone marrow transplantation. J Clin Pathol 1999; 52: 910-13.
49. Jarvis M, Schulz U, Dickinson AM, et al. The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions. J Clin Pathol 2002; 55: 127-32.
50. Dickinson AM, Sviland L, Hamilton PJ, et al. Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 65-70.
51. Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-9.
52. Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005; 116: 923-4.
53. Xu K, Li C, Pan X, et al. Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro. Int J Hematol 2007; 86: 84-90.